Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel, By Region, And Segment Forecasts, 2022

The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 6.9% from 2022 to 2030. The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

Among wet (exudative) and dry (atrophic) age-related macular degeneration, dry AMD is a more prevalent eye disease with 85-90% of cases causing vision damage due to excessive drusen development in the retina. National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.'s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche's Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company's biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Age-related Macular Degeneration Market Report Highlights:

By product, eylea accounted for the largest revenue share in 2021 owing to the higher market penetration and patent protection. Beovu is anticipated to be the fastest-growing segment over the forecast period due to patent protection and superior drying efficacy

By disease type, wet AMD held the largest share in 2021 owing to the availability of major anti-VEGF products including Eylea, Lucentis, and Beovu

North America held the largest market share in 2021 and is expected to dominate over the forecast period due to better reimbursement facilities and the high adoption of novel age-related macular degeneration drugs for the treatment

Based on distribution channel, specialty pharmacy is expected to be the fastest-growing segment during the forecast period owing to increasing collaboration of manufacturers with specialty pharmacies for distributing their products

Product Code: GVR-4-68039-971-3

Chapter 1 Methodology and Scope

1.1 Market segmentation
- 1.1.1 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
- 1.3.1 Purchased database
- 1.3.2 GVR'S internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.3.5 Details of primary research
- 1.3.6 List of primary sources
1.4 Information or data analysis
- 1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
- 1.6.1 Commodity flow analysis
  - 1.6.1.1 Approach 1: Commodity Flow Approach
  - 1.6.1.2 Approach 2: Country - wise market estimation using bottom - up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
1.11 Objectives
- 1.11.1 Objective 1
- 1.11.2 Objective 2
- 1.11.3 Objective 3
- 1.11.4 Objective 4

Chapter 2 Executive Summary

2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

3.1 Market Lineage Outlook
- 3.1.1 Parent market outlook
3.2 Regulatory framework
3.3 Penetration and Growth Prospect Mapping
3.4 Pipeline Analysis, by Phase
- 3.4.1 Key upcoming products
3.5 Market Dynamics
- 3.5.1 Market driver analysis
- 3.5.2 Market restraint analysis
3.6 PESTEL Analysis
3.7 Quality Analysis of the market based route of administration
- 3.7.1 Intravitreal
- 3.7.2 Others
3.8 Epidemiology Analysis
3.9 Unmet Need Analysis

Chapter 4 Global Age - Related Macular DegenerationMarket - Segment Analysis, By Product, 2018 - 2030 (USD Million), Patient Share (%)

4.1 Global Age - Related Macular DegenerationMarket: Product Movement Analysis
4.2 Eylea
- 4.2.1 Eyleaage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
4.3 Lucentis
- 4.3.1 Lucentisage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
4.4 Beovu
- 4.4.1 Beovuage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
4.5 Others
- 4.5.1 Othersage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)

Chapter 5 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Disease Type, 2018 - 2030 (USD Million)

5.1 Global Age - Related Macular DegenerationMarket: Disease Type Movement Analysis
5.2 Dry AMD
- 5.2.1 Dry AMD market estimates and forecast, 2018 - 2030 (USD Million)
5.3 Wet AMD
- 5.3.1 Wet AMD market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

6.1 Global Age - Related Macular DegenerationMarket: Distribution Channel Movement Analysis
6.2 Hospital Pharmacy
- 6.2.1 Hospital Pharmacymarket estimates and forecast, 2018 - 2030 (USD Million)
6.3 Specialty Pharmacy
- 6.3.1 Specialty Pharmacymarket estimates and forecast, 2018 - 2030 (USD Million)
6.4 Online Pharmacy
- 6.4.1 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Age - Related Macular DegenerationMarket: Segment Analysis, by Region, 2018 - 2030 (USD Million)

7.1 Age - Related Macular DegenerationMarket: Regional Movement Analysis
- 7.1.1 North America
  - 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.1.2 U.S.
  - 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.1.3 Canada
  - 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
- 7.1.2 Europe
  - 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.2.2 U.K.
  - 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.2.3 Germany
  - 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.2.4 France
  - 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.2.5 Spain
  - 7.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.2.6 Italy
  - 7.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.1.3 Asia Pacific
  - 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.3.2 Japan
  - 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.3.3 China
  - 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.3.4 India
  - 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.3.5 Australia
  - 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.3.5 South Korea
  - 7.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
- 7.1.4 Latin America
  - 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.4.2 Brazil
  - 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.4.3 Mexico
  - 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.4.4 Argentina
  - 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
- 7.1.5 Middle East & Africa
  - 7.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.5.2 South Africa
  - 7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.5.3 Saudi Arabia
  - 7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.1.5.5 United Arab Emirate
  - 7.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Global Age - Related Macular DegenerationMarket: Competitive Analysis

8.1 Recent Developments and Impact Analysis, by Key Market Participants
- 8.1.1 Major deals & strategic alliances analysis
  - 8.1.1.1 New Product Launches
  - 8.1.1.2 Mergers and Acquisitions
  - 8.1.1.3 Partnerships & Agreements
8.2 Company Categorization
- 8.2.1 Innovators
- 8.2.2 Market Leaders
- 8.2.3 Emerging Players
- 8.2.4 Heat Map Analysis
8.3 Company Market Position Analysis
8.4 Vendor Landscape
- 8.4.1 List of Key Distributors and Channel Partners
- 8.4.2 List of Potential End Users
- 8.4.3 Key Company Market Share Analysis, 2021
8.5 Company Market Share, 2021
- 8.5.1 Competitive Dashboard Analysis
8.6 Private Companies
- 8.6.1 List of Key Emerging Companies
- 8.6.2 Regional Network Map
8.7 Company Profiles
- 8.7.1 F. Hoffmann - La Roche Ltd.
  - 8.7.1.1 Company overview
  - 8.7.1.2 Financial performance
  - 8.7.1.3 Product benchmarking
  - 8.7.1.4 Strategic initiatives
- 8.7.2 Novartis AG
  - 8.7.2.1 Company overview
  - 8.7.2.2 Financial performance
  - 8.7.2.3 Product benchmarking
  - 8.7.2.4 Strategic initiatives
- 8.7.3 Bayer AG
  - 8.7.3.1 Company overview
  - 8.7.3.2 Financial performance
  - 8.7.3.3 Product benchmarking
  - 8.7.3.4 Strategic initiatives
- 8.7.4 Pfizer Inc.
  - 8.7.4.1 Company overview
  - 8.7.4.2 Financial performance
  - 8.7.4.3 Product benchmarking
  - 8.7.4.4 Strategic initiatives
- 8.7.5 Bausch Health Companies Inc.
  - 8.7.5.1 Company overview
  - 8.7.5.2 Financial performance
  - 8.7.5.3 Product benchmarking
  - 8.7.5.4 Strategic initiatives
- 8.7.6 Regeneron Pharmaceuticals Inc.
  - 8.7.6.1 Company overview
  - 8.7.6.2 Product benchmarking
  - 8.7.6.3 Strategic initiatives
- 8.7.7 Amgen Inc.
  - 8.7.7.1 Company overview
  - 8.7.7.2 Financial performance
  - 8.7.7.3 Product benchmarking
- 8.7.8 Biogen
  - 8.7.8.1 Company overview
  - 8.7.8.2 Financial performance
  - 8.7.8.3 Product benchmarking
  - 8.7.8.4 Strategic initiatives
- 8.7.9 Samsung Bioepis
  - 8.7.9.1 Company overview
  - 8.7.9.2 Financial performance
  - 8.7.9.3 Product benchmarking
  - 8.7.9.4 Strategic initiatives

Product Code: GVR-4-68039-971-3

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Age-Related Macular DegenerationMarket, By Region, 2018 - 2030 (USD Million)
Table 4 Global Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 5 Global Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 6 GlobalAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 8 North America Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 9 North America Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 11 U.S. Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 12 U.S.Age-Related Macular DegenerationMarket, By Route of Administration, 2018 - 2030 (USD Million)
Table 13 Canada Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 14 Canada Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 15 Canada Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 16 Europe Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 17 Europe Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 18 Europe Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Germany Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 20 Germany Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 21 Germany Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 22 U.K. Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 23 U.K. Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 24 U.K.Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 France Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 26 France Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 27 France Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 28 Italy Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 29 Italy Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 30 ItalyAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 31 Spain Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 32 Spain Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 33 SpainAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 35 Asia Pacific Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 36 Asia PacificAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 37 Japan Age-Related Macular DegenerationMarket, By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 38 Japan Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 39 JapanAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 China Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 41 China Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 42 China Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 India Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 44 India Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 45 India Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 46 South Korea Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 47 South Korea Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 48 South Korea Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Australia Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 50 Australia Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 51 Australia Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Latin America Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 53 Latin America Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 54 Latin America Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Brazil Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 56 Brazil Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 57 BrazilAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 58 Mexico Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 59 Mexico Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 60 MexicoAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 61 Argentina Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 62 Argentina Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 63 ArgentinaAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 64 Middle East & Africa Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 65 Middle East & Africa Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 66 Middle East & Africa Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Saudi Arabia Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 68 Saudi Arabia Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 69 Saudi Arabia Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 70 South Africa Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 71 South Africa Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 72 South Africa Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
Table 73 UAE Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
Table 74 UAE Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
Table 75 UAEAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Age-Related Macular Degenerationmarket segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Age-Related Macular Degenerationmarket snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Age related macular degenerationmarket driver impact
Fig. 14 Age related macular degenerationmarket restraint impact
Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 16 Industry Analysis - Porter's
Fig. 17 Strategy mapping
Fig. 18 Age-Related Macular Degenerationmarket: Product outlook and key takeaways
Fig. 19 Age-Related Macular Degenerationmarket: Product movement analysis & market share 2021 & 2030
Fig. 20 Eyleaage Related Macular Degenerationmarket estimates and forecast, 2018 - 2030 (USD Million) (Patient Share in %)
Fig. 21 Lucentisage Related Macular Degenerationmarket estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
Fig. 22 Beovu age Related Macular Degeneration market estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
Fig. 23 Others age Related Macular Degeneration market estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
Fig. 24 Age-Related Macular Degenerationmarket: Disease type outlook and key takeaways
Fig. 25 Age-Related Macular Degenerationmarket: Disease Type movement analysis & market share 2021 & 2030
Fig. 26 Dry AMD market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Wet AMD market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Age-Related Macular Degenerationmarket: Distribution channel movement analysis & market share 2021 & 2030
Fig. 29 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Specialty Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Opioids: Regional outlook and key takeaways
Fig. 33 Regional outlook, 2021 & 2030
Fig. 34 North America
Fig. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S.
Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Canada
Fig. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Europe
Fig. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 U.K.
Fig. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Germany
Fig. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 France
Fig. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Italy
Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Spain
Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific
Fig. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Japan
Fig. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
Fig. 56 China
Fig. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 India
Fig. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 South Korea
Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Australia
Fig. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Latin America
Fig. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Brazil
Fig. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Mexico
Fig. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Argentina
Fig. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Middle East & Africa
Fig. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 South Africa
Fig. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Saudi Arabia
Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 UAE
Fig. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Market differentiators
Fig. 81 Key company market share analysis, 2021
Fig. 82 Company market position analysis
Fig. 83 Competitive dashboard analysis
Fig. 84 Regional network map

Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

Description

Table of Contents

List of Tables

Age-related Macular Degeneration Market Growth & Trends:

Age-related Macular Degeneration Market Report Highlights:

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope

Chapter 4 Global Age - Related Macular DegenerationMarket - Segment Analysis, By Product, 2018 - 2030 (USD Million), Patient Share (%)

Chapter 5 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Disease Type, 2018 - 2030 (USD Million)

Chapter 6 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

Chapter 7 Age - Related Macular DegenerationMarket: Segment Analysis, by Region, 2018 - 2030 (USD Million)

Chapter 8 Global Age - Related Macular DegenerationMarket: Competitive Analysis

List of Tables

List of Figures